HIMA workshop
This article was originally published in The Gray Sheet
Executive Summary
Topics for discussion at the eighth annual Health Industry Manufacturers Association device submissions workshop June 27-29 include FDA's allocation of resources for implementation of the FDA Modernization Act, 510(k) and premarket approval application reengineering initiatives, advertising and promotion, labeling and expedited review. Device center staffers scheduled to speak include: Susan Alpert, director of FDA's Office of Device Evaluation, Phil Phillips, ODE deputy director, and Byron Tart, director, promotion and advertising policy staff. The conference is being held at the Omni Shoreham hotel in Washington, D.C. Contact James Blanchard at 202/434-7231 for additional information...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.